March 6 (Reuters) - Medicus Pharma Ltd MDCX.O:
MEDICUS PHARMA LTD ANNOUNCES POSITIVELY TRENDING INTERIM ANALYSIS FOR SKNJCT-003 PHASE 2 CLINICAL STUDY TO NON-INVASIVELY TREAT BASAL CELL CARCINOMA OF THE SKIN $(BCC)$
MEDICUS PHARMA LTD: D-MNA WAS WELL TOLERATED FOR BOTH DOSE LEVELS
MEDICUS PHARMA: PLANS TO SUBMIT ANALYSIS TO FDA UNDER PACKAGE SEEKING TYPE C MEETING WITH FDA IN Q2
Source text: ID:nGNX8f3W0v
Further company coverage: MDCX.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。